MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Helping small businesses create jobs
Rep. Chris Van Hollen has written an Op-Ed in Politico about his efforts to help small businesses like Sanaria create good, quality jobs in Maryland. Read the full story!
Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria’s PfSPZ vaccine
Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine.
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine
Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University.
Dr. David Dolberg, Sanaria’s Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer
Sanaria Inc. is proud to recognize and celebrate the role of Dr. David Dolberg, Esq. ‐ Sanaria’s intellectual property attorney ‐ in helping to shape current approaches to the understanding and treatment of cancer. Prior to launching a career in law, David was a postdoctoral fellow in the laboratory of Dr. Mina Bissell at Berkeley, who was recently highlighted in a New York Times article by Gina Kolata, “Old Ideas Spur New Approaches in Cancer Fight” (December 29, 2009).
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process
Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million.
Why a Man Let 2,000 Malaria-Infected Mosquitoes Bite Him
Some people will go to extreme lengths to avoid mosquito bites. They'll wear long sleeves and pants in the heat of summer, surround themselves with citronella candles and torches, and spray foul-smelling chemicals all over their bodies—or simply not set foot outside when they know the bugs are biting. Stephen Hoffman isn't quite like those people.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.